In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

International Journal of Antimicrobial Agents

Volumn 51, Issue 1, 2018, Pages 62-64

  Seifert, Harald ^a,b   Stefanik, Danuta ^a   Sutcliffe, Joyce A ^a,c   Higgins, Paul G ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b German Center for Infection Research (DZIF)   (Germany)

^c Tetraphase Pharmaceuticals   (United States)

Author keywords

Colistin; International clone; Multidrug resistance; Oxacillinase; Tetracycline; Tigecycline

Indexed keywords

AMIKACIN; CARBAPENEM; COLISTIN; DOXYCYCLINE; ERAVACYCLINE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; SULBACTAM; TIGECYCLINE; TOBRAMYCIN; 7-FLUORO-9-PYRROLIDINOACETAMIDO-6-DEMETHYL-6-DEOXYTETRACYCLINE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; BETA-LACTAMASE OXA-51, ACINETOBACTER BAUMANNII; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DILUTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTION; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; TETRACYCLINES;

EID: 85039423338     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.06.022     Document Type: Article

References (20)

1. Peleg, A.Y., Seifert, H., Paterson, D.L., Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 (2008), 538–582.
2. Poirel, L., Nordmann, P., Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12 (2006), 826–836.
3. Higgins, P.G., Dammhayn, C., Hackel, M., Seifert, H., Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 65 (2010), 233–238.
4. Coyne, S., Courvalin, P., Perichon, B., Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 55 (2011), 947–953.
5. Cheah, S.E., Li, J., Tsuji, B.T., Forrest, A., Bulitta, J.B., Nation, R.L., Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother 60 (2016), 3921–3933.
6. Zhanel, G.G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 76 (2016), 567–588.
7. Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N., In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother 60 (2016), 3840–3844.
8. Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., Quale, J., Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 59 (2015), 1802–1805.
9. Clinical and Laboratory Standards Institute (CLSI), M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—tenth edition. CLSI, Wayne, PA, USA, 2015.
10. th ed. CLSI supplement M100S. CLSI, Wayne, PA, USA, 2016.
11. Woodford, N., Ellington, M.J., Coelho, J.M., Turton, J.F., Ward, M.E., Brown, S., et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27 (2006), 351–353.
12. Tomaschek, F., Higgins, P.G., Stefanik, D., Wisplinghoff, H., Seifert, H., Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of Acinetobacter baumannii outbreak and sporadic isolates. PLoS ONE, 11, 2016 e0153014.
13. Jones, C.L., Clancy, M., Honnold, C., Singh, S., Snesrud, E., Onmus-Leone, F., et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis 61 (2015), 145–154.
14. Pagano, M., Barin, J., Martins, A.F., Zavascki, A.P., High endemic rates of OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates caused by the persistence of major clones in hospitals in a Brazilian city 5 years after an outbreak. Infect Control Hosp Epidemiol 36 (2015), 860–862.
15. Garnacho-Montero, J., Dimopoulos, G., Poulakou, G., Akova, M., Cisneros, J.M., De Waele, J., et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med 41 (2015), 2057–2075.
16. Dickstein, Y., Leibovici, L., Yahav, D., Eliakim-Raz, N., Daikos, G.L., Skiada, A., et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open, 6, 2016, e009956.
17. Testa, R., Cantón, R., Giani, T., Morosini, M.I., Nichols, W.W., Seifert, H., et al. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates. Int J Antimicrob Agents 45 (2015), 641–646.
18. Hornsey, M., Ellington, M.J., Doumith, M., Thomas, C.P., Gordon, N.C., Wareham, D.W., et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 65 (2010), 1589–1593.
19. Solomkin, J.S., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 152 (2017), 224–232.
20. Connors, K.P., Housman, S.T., Pope, J.S., Russomanno, J., Salerno, E., Shore, E., et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 58 (2014), 2113–2118.